A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues

Cancer Research

Volumn 63, Issue 1, 2003, Pages 100-106

  Krynetski, Eugene Y ^b   Krynetskaia, Natalia F ^b   Bianchi, Marco E ^a   Evans, William E ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; CYTARABINE; DEOXYTHIOGUANOSINE; DNA NUCLEOTIDYLEXOTRANSFERASE; FLOXURIDINE; FLUDARABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; MERCAPTOPURINE; NUCLEAR PROTEIN; NUCLEOSIDE DERIVATIVE; PROTEIN DISULFIDE ISOMERASE; TIOGUANINE; VINCRISTINE;

AMINO ACID SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; DRUG DNA BINDING; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MISMATCH REPAIR; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; CALRETICULIN; CELL CYCLE; CELL SURVIVAL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HIGH MOBILITY GROUP PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KINETICS; LEUKEMIA, B-CELL; MACROMOLECULAR SUBSTANCES; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0037228781     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis; a link between cancer genetics and chemotherapy. Cell. 108: 153-164, 2002.
2. Huang, P., and Plunkett, W. Fludarabine- and gemcitabine-induced apoptosis: incorpotation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol., 36: 181-188, 1995.
3. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
4. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
5. Nelms, B. E., Maser, R. S., MacKay, J. F., Lagally, M. G., and Petrini, J. H. In situ visualization of DNA double-strand break repair in human fibroblasts. Science (Wash. DC), 280: 590-592, 1998.
6. Paull, T. T., Cortez, D., Bowers, B., Elledge, S. J., and Gellert, M. From the cover: direct DNA binding by Brca1. Proc. Natl. Acad. Sci. USA, 98: 6086-6091, 2001.
7. Griffin, S., Branch, P., Xu, Y. Z., and Karran, P. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry, 33: 4787-4793, 1994.
8. Krynetski, E. Y., Krynetskaia, N. F., Gallo, A. E., Murti, K. G., and Evans, W. E. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol. Pharmacol., 59: 367-374, 2001.
9. Elion, G. B. The purine path to chemotherapy. Science (Wash. DC), 244: 41-47, 1989.
10. LePage, G. A. Basic biochemical effects and mechanism of action of 6-thioguanine. Cancer Res., 23: 1202-1206, 1963.
11. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville E. A., Pommier, Y., Botstein, D., Brown P. O., and Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer [see comments]. Nat. Genet., 24: 236-244, 2000.
12. Somerville, L., Krynetski, E. Y., Krynetskaia, N. F., Beger, R. D., Zhang, W., Marhefka, C. A., Evans, W. E., and Kriwacki, R. W. Structure and dynamics of thioguanine-modified duplex DNA. J. Biol. Chem., 27B, 2003.
13. Krynetskaia, N. F., Krynetski, E. Y., and Evans, W. E. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol. Pharmacol., 56: 841-848, 1999.
14. Krynetskaia, N. F., Cai, X., Nitiss, J. L., Krynetski, E, Y., and Relling, M. V. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J., 14: 2339-2344, 2000.
15. Relling, M. V., Yanishevski, Y., Nemec, J., Evans, W. E., Boyett, J. M., Behm, F. G., and Pui, C. H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (Baltimore) 12: 346-352 1998.
16. Relling, M. V., Rubnitz, J. E., Rivera, G. K., Boyett, J. M., Hancock, M. L., Felix, C.A. Kun L. E., Walter, A. W., Evans, W. E., and Pui, C. H. High incidence of secondary brain tumours after radiotherapy and antimetabolites [see comments]. Lancet, 354: 34-39, 1999.
17. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (Lond.), 22: 1931-1937, 2001.
18. Pichierri, P., Franchitto, A., Piergentili, R., Colussi, C., and Palitti, F. Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair. Carcinogenesis (Lond.), 22: 1781-1787, 2001.
19. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11: 1475-1489, 1983.
20. Bianchi, M. E., Beltrame, M., and Paonessa, G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science (Wash. DC), 243: 1056-1059, 1989.
21. Calogero, S., Grassi, F., Aguzzi, A., Voigtlander, T., Ferrier, P., Ferrari, S., and Bianchi, M. E. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet., 22: 276-280, 1999.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
23. Krynetski, E. Y., and Evans, W. E. Mercaptopurine and related compounds. In: H. P. Lipp (ed.), Anticancer Drug Toxicity, pp. 392-429. New York: Marcel Dekker, Inc., 1999.
24. Fairchild, C. R., Maybaum, J., and Kennedy, K. A. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem. Pharmacol., 35: 3533-3541, 1986.
25. Christie, N. T., Drake, S., Meyn, R., and Nelson, J. A. 6-thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res., 44: 3665-3671, 1984.
26. da Silva, C. P., de Oliveira, C. R., da Conceicao, M., and de Lima, P. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol. 51: 1331-1340, 1996.
27. Hortelano, S., and Bosca, L. 6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Mol. Pharmacol., 51: 414-421, 1997.
28. Tsurusawa, M., Saeki, K., and Fujimoto, T. Differential induction of apoptosis on human lymphoblastic leukemia Nalm-6 and Molt-4 cells by various antitumor drugs. Int. J. Hematol., 66: 79-88, 1997.
29. Achanta, G., Pelicano, H., Feng. L., Plunkett, W., and Huang, P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res., 61: 8723-8729, 2001.
30. Bustin, M., and Reeves, R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol., 54: 35-100, 1996.
31. Bustin, M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol., 19: 5237-5246, 1999.
32. Ferraro, A., Altieri, F., Coppari, S., Eufemi, M., Chichiarelli, S., and Turano, C. Binding of the protein disulfide isomerase isoform ERp60 to the nuclear matrix-associated regions of DNA. J. Cell Biochem., 72: 528-539, 1999.
33. Sirover, M. A. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim. Biophys. Acta, 1432: 159-184, 1999.
34. Jim M. L., Zhang, P., Ding, M. X., Yun, J. P., Chen, P. F., Chen, Y. H., and Chew, Y. Q. Altered expression of nuclear matrix proteins in etoposide-induced apoptosis in HL-60 cells. Cell Res., 11: 125-134, 2001,
35. Xanthoudakis, S., and Nicholson, D. W. Heat-shock proteins as death determinants. Nat. Cell Biol., 2: E163-E165, 2000.
36. Cohen, S. M., and Lippard, S. J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol., 67: 93-130, 2001.
37. Pasheva, E. A., Ugrinova, I., Spassovska, N. C., and Pashev, I. G. The binding affinity of HMG1 protein to DNA modified by cisplatin and its analogs correlates with their antitumor activity. Int. J. Biochem. Cell Biol., 34: 87-92, 2002.
38. Marathias, V. M., Jerkovic, B., and Bolton, P. H. Damage increases the flexibility of duplex DNA. Nucleic Acids Res., 27: 1854-1858, 1999.
39. Lipp, H. P., and Bokemeyer, C. Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity. In: H. P. Lipp (ed.), Anticancer Drug Toxicity, pp. 11-201. New York: Marcel Dekker, Inc., 1999.
40. Scaffidi, P., Misteli, T., and Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (Lond.), 418: 191-195, 2002.
41. Bustin, M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB 1. Sci STKE., 2002: PE39, 2002.
42. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem., 68: 850-858, 1996.